ProstaLund AB - Interim report January-March 2024
January 1 - March 31
- Net sales reached SEK 3,5 (5,5) million
- Operating profit/loss totaled SEK -4,7 million (-3,1) million
- Loss after taxes SEK -4,8 (-3,1) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,06 (-0,06)
- Cash flow from operating activities amounted to SEK -6,6 (-5,5) million
- Cash and cash equivalents amounted to SEK 6,9 (5,9) million as per March 31, 2024
Significant events during the period
- New management team appointed on February 15
- Schelin Catheters – new study published on February 27
Significant events after the end of the period
- Two new studies with ProstaLund’s Schelin Catheter® presented at the EAU in Paris on April 8
- Positive results from unannounced inspection by TÜV SÜD conducted on April 9-10
- ProstaLund and Capio Specialistcenter AB signed a new agreement regarding disposable materials used in CoreTherm® treatments. The agreement is over 12 months, with an option to extend. The order value is approximately SEK 1,3 million over the contract period. The agreement replaces the previous agreement with Capio Specialistcenter AB.
- Prostalund informed on May 16 that the Board of Directors intends to decide on a rights issue of units for an initial issue amount of around 29 MSEK
| (SEK MILLION) | JAN-MAR 2024 | JAN-MAR 2023 | JAN-DEC 2023 | JAN-DEC 2022 |
| Net sales | 3,5 | 5,5 | 22,1 | 17,2 |
| Gross Margin, % | 69,7 | 68,2 | 70,1 | 74,2 |
| Operating profit/loss, EBIT | -4,7 | -3,1 | -16,9 | -10,9 |
| Cash flow from operating activites | -6,6 | -5,5 | -23,7 | -16,4 |
| Cash and cash equivalents | 6,9 | 5,9 | 15,0 | 11,9 |
| Average number of employees | 6 | 7 | 8 | 8 |
”Despite a weaker quarter in terms of sales, we are positive about the underlying treatments and needs of our customers and the continued interest in our stand-alone products from an international perspective”
Anders Kristensson
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.